You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ZOLMITRIPTAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zolmitriptan patents expire, and what generic alternatives are available?

Zolmitriptan is a drug marketed by Padagis Israel, Alembic, Apotex Inc, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Rising, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Ani Pharms, Appco, Aurobindo Pharma, Invagen Pharms, Natco Pharma Usa, Orbion Pharms, Pld Acquisitions Llc, Sun Pharma Global, and Zydus Pharms. and is included in twenty-three NDAs.

The generic ingredient in ZOLMITRIPTAN is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zolmitriptan

A generic version of ZOLMITRIPTAN was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14th, 2013.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZOLMITRIPTAN?
  • What are the global sales for ZOLMITRIPTAN?
  • What is Average Wholesale Price for ZOLMITRIPTAN?
Drug patent expirations by year for ZOLMITRIPTAN
Drug Prices for ZOLMITRIPTAN

See drug prices for ZOLMITRIPTAN

Recent Clinical Trials for ZOLMITRIPTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Parc de Salut MarPhase 1
Food and Drug Administration (FDA)Phase 1
William StoopsEarly Phase 1

See all ZOLMITRIPTAN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ZOLMITRIPTAN
Paragraph IV (Patent) Challenges for ZOLMITRIPTAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZOMIG Nasal Spray zolmitriptan 2.5 mg/spray 021450 1 2016-06-09
ZOMIG Nasal Spray zolmitriptan 5 mg/spray 021450 1 2013-11-14

US Patents and Regulatory Information for ZOLMITRIPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pld Acquisitions Llc ZOLMITRIPTAN zolmitriptan TABLET;ORAL 207867-001 Feb 27, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Invagen Pharms ZOLMITRIPTAN zolmitriptan TABLET;ORAL 204284-002 Apr 9, 2014 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms ZOLMITRIPTAN zolmitriptan TABLET;ORAL 203019-001 Jul 11, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma ZOLMITRIPTAN zolmitriptan TABLET;ORAL 207021-002 May 11, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Jubilant Generics ZOLMITRIPTAN zolmitriptan TABLET;ORAL 202279-001 Nov 20, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.